By Dean Seal
CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, leading to a selloff of its shares.
The biopharmaceutical company said Tuesday that superiority in overall survival had been the primary endpoint of the trial for Berubicin, though the treatment still shows a favorable safety profile. An analysis of the trial's outcomes is still ongoing, CNS said.
Shares fell 55% to $1.52 in premarket trading.
The trial was comparing Berubicin to Lomustine, which is the current standard of care in recurrent or progressive Glioblastoma Multiforme.
CNS said the trial data shows overall survival is comparable between the two treatments, including for patients with the most unfavorable tumor markers.
"We are awaiting long-term follow-up of patients still alive as well as those still on trial, and will evaluate our substantial clinical dataset to obtain additional insights," Chief Medical Officer Sandra Silberman said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 25, 2025 08:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。